Clinical experience with Escherichia coli rHuGM-CSF

A C Stern1, T C Jones

  • 1Sandoz Pharma Ltd., Basel, Switzerland.

International Review of Experimental Pathology
|January 1, 1993
PubMed

Insights

Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) reduces infections and intensive care days, improving chemotherapy adherence. Recommended doses are well-tolerated and beneficial for myeloid disorders and post-transplant care.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are associated with increased infection risk.
  • Bone marrow transplantation (BMT) can lead to prolonged intensive care unit (ICU) stays.
  • Cancer chemotherapy and certain viral infections (e.g., AIDS, cytomegalovirus retinitis) can cause myeloid hypoplasia.

Purpose of the Study:

  • To evaluate the clinical benefits of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF).
  • To assess the safety and efficacy of rHuGM-CSF in patients with myelodysplastic syndromes, aplastic anemia, post-bone marrow transplant, and viral infections.
  • To determine optimal dosing to maximize therapeutic effects while minimizing adverse reactions.

Main Methods:

  • Clinical use of rHuGM-CSF in patients with various hematologic and oncologic conditions.
  • Monitoring of infection rates, intensive care unit (ICU) days, chemotherapy adherence, and antiviral drug efficacy.
  • Dose-ranging studies to identify effective and safe dosage levels.

Main Results:

  • rHuGM-CSF significantly reduced infections in patients with MDS and AA.
  • Reduced ICU days were observed in allogeneic bone marrow transplant (ABM transplant) recipients.
  • Improved adherence to chemotherapy protocols and enhanced efficacy of antiviral therapies were noted.

Conclusions:

  • rHuGM-CSF is a valuable adjunctive therapy for managing dysmyelopoiesis and myeloid hypoplasia.
  • Recommended doses of rHuGM-CSF are well-tolerated and demonstrate significant patient benefit.
  • High doses of rHuGM-CSF should be avoided due to increased adverse reactions and a plateau in biological response.